A research team led by Associate Professor Ser Wee from the Nanyang Technological University, Singapore (NTU Singapore) and Associate Professor David Foo from the Tan Tock Seng Hospital (TTSH) have invented a smart handheld medical device that could enable early intervention for patients with congestive heart failure.
The portable innovation, which resembles a stethoscope, is made up of an acoustic sensor connected to a smartphone. It enables early intervention by allowing patients to check for excess fluid in the lungs at home. Fluid accumulation in the lungs, which causes breathlessness, is a common symptom of congestive heart failure.
One in five people worldwide run the risk of developing congestive heart failure, and this prevalence increases with age. As there is no cure for the ailment, patients can only monitor their health closely with lifestyle changes or medication to prevent their heart function from deteriorating irreversibly. Currently, patients can only check for fluid accumulation in the lungs by going for a clinical examination, which can be considerably subjective, or through imaging modalities and serum biomarker tests, which are costly and take a longer time.
The new non-invasive device circumvents these problems with its portability, ease of use and quick results. Currently a prototype, the device is able to detect any excess fluid in the lungs in 10 seconds once placed on the patient’s chest or back. In a pilot study using lung sounds recorded from TTSH’s congestive heart failure patients, Assoc Prof Ser and his team found the device to have over 92 per cent accuracy in identifying patients with the condition – comparable to existing ‘gold standard’ diagnosis methods such as X-rays and CT scans. Associate Professor Foo said, “Patients can monitor their condition at home and use the device whenever they feel slightly breathless at home. It is potentially a game-changer in the management of ambulatory heart failure patients. It can also provide a rapid and accurate acute diagnosis of heart failure in situations of undifferentiated shortness of breath symptoms.”
Associate Professor Ser added, “Currently, such diagnosis can only be conducted through clinical examination, which cannot be made frequently. Our smart medical device can be used by anyone, anywhere and any number of times, which will enable the possibility of early intervention of congestive heart failure. The next wave of MedTech start-ups will see the massive proliferation of smart medical devices that rely on artificial intelligence and sensing technologies, such as the one we invented, and that will enable personalised self-assessment and screening of cardiopulmonary and other diseases, and revolutionise the way healthcare is managed in future.”
How it works
In congestive heart failure, the diseased or overworked heart ventricle is unable to pump out enough of the blood it receives from the lungs. This causes pressure to build up first in the heart, then in the veins and capillaries in the lungs. The pressure then pushes fluid back through the capillary walls and into the air sacs of the lungs. As a result, when air passes through these fluid-filled air sacs, crackles can be heard from the lungs. Depending on the intensity, a crackle may sound like salt added to a hot pan, or Velcro being torn apart. Based on this principle, Prof Ser and his team found a unique set of features that can be used to identify characteristics of sounds unique to patients with fluid accumulation in the lungs. They then developed a proprietary AI algorithm capable of identifying and processing these signals to determine if there is fluid accumulation in the lungs.
The smart medical device first picks up breathing sounds through a sound sensor. Through a mobile app, the sound signals are then sent to a server located in the cloud. The NTU-developed algorithm stored in the cloud then processes these sound signals, and the results are shown on the mobile app. This whole process takes about 10 seconds to complete. Following two rounds of tests with samples collected from 86 patients, the team is now running a third round of tests on the device to further validate its sensitivity and specificity.
Source: Nanyang Technological University